Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413781 | 0.95 | HDAC1 (0.33) | HDAC1HDAC6SLC29A1NR3C1SMN1; SMN2 | |
| SCHEMBL4415135 | 0.90 | PKM (0.30) | — | |
| SCHEMBL4415457 | 0.89 | — | — | |
| SCHEMBL4415042 | 0.87 | F9 (0.30) | — | |
| SCHEMBL4419396 | 0.86 | ABL1 (0.34) | SMN1; SMN2PDE7A | |
| SCHEMBL4415040 | 0.84 | — | — | |
| SCHEMBL4411280 | 0.84 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL4418039 | 0.81 | — | — | |
| SCHEMBL4417020 | 0.80 | PKM (0.31) | SMN1; SMN2 | |
| SCHEMBL4421662 | 0.80 | ABL1 (0.36) | SMN1; SMN2PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651642-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-11-04 | — | — | EP | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1651642-A4 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2006-11-29 | — | — | EP | disclosed |
| EP-1651642-A1 | PNA MONOMER AND PRECURSOR | Panagene Inc. (KR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026930-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009998-A1 | PNA MONOMER AND PRECURSOR | PANAGENE INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026930-A1 | PNA monomer and precursor | RNGTT, POLL, NSUN3 | HDAC1 4202/4885HDAC6 3499/4885SLC29A1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.